Celebrity Inventors
Magician Harry Houdini patented a "Diver's Suit" enabling the wearer to "quickly divest himself of the suit while being submerged and to safely escape and reach the surface of the water."
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8187600 | Polypeptides capable of binding to CD64 comprising one or more heterologous T cell epitopes and their uses The invention relates to the use of a polypeptide that comprises i) a first portion comprising the part of human Fc that binds to CD64, and ii) a second portion comprising one or more heterologous T cell epitopes for stimulating a cytotoxic T cell response. The poly... | 05/29/2012 |
| 8182812 | Human monoclonal antibodies against CD25 Isolated human monoclonal antibodies which bind to and inhibit human CD25, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a hybridoma, a transfectoma or in a nonhuman transgenic animal, e.g., a transgeni... | 05/22/2012 |
| 8173126 | Blood VEGF level-lowering agent containing IL-6 antagonist as the active ingredient A blood vascular endothelial growth factor (VEGF) level-lowering agent comprising an interleukin-6 (IL-6) antagonist as an active ingredient. ... | 05/08/2012 |
| 8168185 | Process for the purification of anti CD-25 antibodies The invention relates to a process for the purification of an Fc-containing protein based on cation exchange chromatography. ... | 05/01/2012 |
| 8168183 | Antibodies to granulocyte-macrophage colony-stimulating factor The current invention relates to high-affinity antibodies to Granulocyte-Macrophage Colony-Stimulating Factor that have reduced immunogenicity when administered to a human to treat diseases and method of using such antibodies. ... | 05/01/2012 |
| 8168184 | Bi-specific monoclonal antibody (specific for both CD3 and CD11B) therapeutic drug The present invention relates to the treatment of immune system abnormalities that can be found in lethal human cancers and also in the progressive Human Immunodeficiency Virus Type 1 (HIV-1) infections and provides medicaments to correct abnormalities in a subject ... | 05/01/2012 |
| 8163282 | Monoclonal antibody capable of binding to heparin-binding epidermal growth factor-like growth factor Medicaments for treating diseases related to HB-EGF escalation are in demand. The present invention provides a monoclonal antibody or an antibody fragment thereof which binds to a cell membrane-bound HB-EGF, a membrane type HB-EGF and a secretory HB-EGF. ... | 04/24/2012 |
| 8163283 | Monoclonal antibodies against gonadotropin-releasing hormone receptor Monoclonal antibodies against gonadotropin releasing hormone (GnRH) receptor induce cellular apoptosis of various cancer cells expressing this surface receptor. The monoclonal antibodies and their humanized forms, or fragments thereof, can serve as anti-cancer agent... | 04/24/2012 |
| 8163284 | Methods of treating TSLP-related inflammatory disorders The present disclosure provides compositions and methods relating to antigen binding proteins which bind to human thymic stromal lymphopoietin (TSLP), including antibodies. In particular embodiments, the disclosure provides fully human, humanized and chimeric anti-T... | 04/24/2012 |
| 8158124 | Compositions and methods for binding lysophosphatidic acid Compositions and methods for making and using anti-LPA agents, for example, monoclonal antibodies, are described. ... | 04/17/2012 |
| 8153126 | Anti-αβantibodies Monoclonal antibodies that specifically bind to □v□□. Also included are methods of using these antibodies to treat mammals having or at risk of having □v□6-mediated diseases, or to diagnose □V□6-mediated diseases. ... | 04/10/2012 |
| 8153125 | CD20 binding molecules The present invention relates to CD20 binding molecules and nucleic acid sequences encoding CD20 binding molecules. In particular, the present invention relates to CD20 binding molecules with a high binding affinity, and a low dissociation rate, with regard to human... | 04/10/2012 |
| 8147834 | Anti-TGF-beta receptor II antibodies The present invention is directed to antibodies against human transforming growth factor beta receptor II (TGFβRII), pharmaceutical compositions comprising antibodies and methods of using the antibodies, alone or in combination, for example, for treating cancer and... | 04/03/2012 |
| 8147833 | Prevention and treatment of synucleinopathic and amyloidogenic disease The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic ... | 04/03/2012 |
| 8147832 | CD20-binding polypeptide compositions and methods A CD20-binding polypeptide composition comprising a combination of a modified heavy chain variable region polypeptide and a modified light chain variable region polypeptide. The combination can be (a) a modified 2B8 antibody heavy chain variable region polypeptide o... | 04/03/2012 |
| 8142780 | Anti-bacterial antibodies A pharmaceutical composition includes a purified antibody and a pharmaceutically acceptable carrier. The antibody can be a monoclonal antibody having both an antigen-binding portion that binds at least one bacterial antigen and a constant region that does not bind s... | 03/27/2012 |
| 8137669 | Elimination of heterogeneous or mixed cell population in tumors Methods of killing or inhibiting tumors comprising of heterogeneous or mixed cell populations is described. The killing or inhibition of tumors is achieved by selectively targeting a unique ligand suspected of being expressed on a particular cell population to also ... | 03/20/2012 |
| 8137668 | Methods and compositions for generating human monoclonal antibodies The present invention provides a method for generating human monoclonal antibodies, especially those that are specific for surface antigens representative of a particular cell type. The present invention also includes populations of monoclonal antibodies produced by... | 03/20/2012 |
| 8128929 | Antibodies against PDGFRa The invention provides antibodies that bind to human PDGFRα and neutralize activation of the receptor. The invention further provides methods for neutralizing activation of PDGFRα and methods of treating a mammal with a neoplastic disease using the antibodies alon... | 03/06/2012 |
| 8128928 | Humanized antibodies that recognize beta amyloid peptide The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient. Preferred agents include humanized antibodies. ... | 03/06/2012 |
| 8128930 | Anti-ADDL antibodies and uses thereof The present invention relates to antibodies that differentially recognize multi-dimensional conformations of Aβ-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extr... | 03/06/2012 |
| 8124080 | Human monoclonal antibody having fat-reducing effect A purified polypeptide having an amino acid sequence that is substantial identical with the amino acid sequence of SEQ ID NO:1, SEQ ID NO:3, or both, in which the polypeptide binds low density lipoproteins (LDL) or oxidized LDL (oxLDL), or both, and particularly bin... | 02/28/2012 |
| 8124081 | Prevention and treatment of amyloidogenic diseases Disclosed are pharmaceutical compositions and methods for preventing or treating a number of amyloid diseases, including Alzheimer's disease, prion diseases, familial amyloid neuropathies and the like. The pharmaceutical compositions include immunologically reactive... | 02/28/2012 |
| 8124083 | Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells This invention relates to the use of monoclonal and polyclonal antibodies that specifically bind to and have the ability in the alternative to become internalized by cells expressing folate receptor alpha (FRA) and to induce an immune effector activity such as antib... | 02/28/2012 |
| 8124082 | Humanized anti-beta7 antagonists and uses therefor The invention provides therapeutic anti-beta7 antibodies, compositions comprising, and methods of using these antibodies. ... | 02/28/2012 |
| 8119134 | Method for extending pregnancy in patients exhibiting at least one symptom of preeclampsia and eclampsia A composition is provided to prevent, limit the effects of, delay the onset of, or treat one or more of the causes, symptoms or complications of gestational hypertension, preeclampsia, eclampsia and/or intrauterine growth restriction. The composition comprises a the... | 02/21/2012 |
| 8119132 | Humanized anti-tag-72 monoclonal antibodies The present invention relates to humanized antibodies specific to a tumor-associated glycoprotein, TAG-72, and anticancer compositions comprising the humanized antibodies. In detail, the present invention relates to a humanized antibody which has enhanced antigen bi... | 02/21/2012 |
| 8119133 | Engineered anti-IL-23R antibodies Antibodies to human IL-23R are provided, as well as uses thereof, e.g. in treatment of inflammatory, autoimmune, and proliferative disorders. ... | 02/21/2012 |
| 8114400 | Aza-bicyclic compounds and their use as stimulators of soluble guanylate cyclase The present application relates to novel azabicyclic compounds, processes for their preparation, their use alone or in combinations for the treatment and/or prevention of diseases, and their use for producing medicaments for the treatment and/or prevention of diseas... | 02/14/2012 |
| 8105592 | Heavy chain and single domain antibodies The present invention relates to heavy chain immunoglobulins or fragments thereof of the VHH or VNAR type, or domain antibodies (dAbs) of the heavy or light chains of immunoglobulins or fragments thereof, suitable for use in the management of infections, in particul... | 01/31/2012 |
| 8105593 | Anti-ADDL monoclonal antibody and use thereof The present invention relates to antibodies that differentially recognize multi-dimensional conformations of Aβ-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extr... | 01/31/2012 |
| 8101179 | Anti-CD20 monoclonal antibody A murine anti-CD20 monoclonal antibody having cell growth inhibitory activities is disclosed. Cell growth inhibitory activities include apoptosis against human CD20 antigen expressing cells in culture of the CD20 antigen expressing cells without effector cells. The ... | 01/24/2012 |
| 8101180 | Anti-IGF-IR and/or anti-insulin/IGF-I hybrid receptors antibodies and uses thereof The present invention relates to novel antibodies capable of binding specifically to the human insulin-like growth factor I receptor (IGF-IR) and/or the insulin/IGF-I hybrid receptor (hybrid-R) and/or capable of specifically inhibiting the tyrosine kinase activity o... | 01/24/2012 |
| 8101178 | Antibodies directed to tumor necrosis factor and uses thereof Antibodies directed to the antigen TNFα and uses of such antibodies. In particular, fully human monoclonal antibodies directed to the antigen TNFα. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, ... | 01/24/2012 |
| 8097251 | Functional heavy chain antibodies, fragments thereof, library thereof and methods of production thereof The present invention relates to functional heavy chain antibodies, functional single domain heavy chain antibodies, functional VH domains, or functional fragments thereof including an amino acid which is neither a charged amino acid nor a C at position 45, and incl... | 01/17/2012 |
| 8092801 | Prevention and treatment of synucleinopathic and amyloidogenic disease The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic ... | 01/10/2012 |
| 8092800 | Antibodies against antigens This invention relates to domain antibodies. In particular, it relates to domain antibodies (dAbs) that recognize virulence traits of Candida spp. and confer passive protection against candidiasis. ... | 01/10/2012 |
| 8092802 | High affinity human antibodies to human IL-4 receptor The present invention provides methods for treating one or more diseases or disorders which are improved, inhibited or ameliorated by reducing interleukin-4 (IL-4) activity. The methods of the invention comprise administering to a patient an antibody, or antigen-bin... | 01/10/2012 |
| 8088378 | Anti-CD79B antibodies and immunoconjugates and methods of use The present invention is directed to anti-CD79b antibody, huMA79b.v28, and compositions of matter thereof useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same. ... | 01/03/2012 |
| 8088379 | Modified T cell receptors and related materials and methods The invention is directed to a modified T cell receptor (TCR) comprising an amino acid sequence of a wild-type (WT) TCR with no more than three amino acid substitutions, wherein the modified TCR, as compared to the WT TCR, (i) has an enhanced ability to recognize ta... | 01/03/2012 |
